SU5416 (Semaxanib): Selective VEGFR2 Inhibitor for Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a small-molecule inhibitor that selectively targets VEGFR2 (Flk-1/KDR), disrupting VEGF-induced endothelial signaling and angiogenesis [APExBIO product page]. It demonstrates potent in vitro activity with an IC₅₀ of 0.04±0.02 μM for VEGF-driven mitogenesis in HUVECs and effective in vivo tumor growth inhibition at 1–25 mg/kg in murine xenograft models (Zhang et al., 2024). SU5416 also acts as an agonist of the aryl hydrocarbon receptor (AHR), inducing indoleamine 2,3-dioxygenase (IDO) and promoting regulatory T cell differentiation. Its dual mechanism enables research into both cancer biology and immune modulation. The compound is insoluble in water and ethanol but dissolves at ≥11.9 mg/mL in DMSO, ensuring experimental flexibility for preclinical workflows.

Biological Rationale

Angiogenesis is essential for tumor growth and metastasis. VEGFR2 (also known as Flk-1/KDR) is a receptor tyrosine kinase that mediates the angiogenic effects of vascular endothelial growth factor (VEGF). Inhibiting VEGFR2 interrupts the VEGF-driven signaling cascade, suppressing endothelial cell proliferation and new blood vessel formation. This disruption results in diminished tumor vascularization and reduced tumor progression. SU5416 (Semaxanib) was developed as a selective VEGFR2 inhibitor to provide researchers with a precise tool for dissecting angiogenic processes in cancer and vascular pathologies [APExBIO]. Beyond angiogenesis, SU5416’s AHR agonist activity introduces an immunomodulatory dimension, relevant to studies on autoimmune diseases and transplant tolerance. These dual roles make SU5416 a valuable probe in preclinical models of cancer, immune regulation, and vascular disease.

Mechanism of Action of SU5416 (Semaxanib) VEGFR2 Inhibitor

SU5416 (Semaxanib) acts as a highly selective inhibitor of the vascular endothelial growth factor receptor 2 (VEGFR2), also referred to as Flk-1/KDR. It binds to the ATP-binding site of VEGFR2, blocking its kinase activity. This prevents VEGF-induced phosphorylation events that trigger downstream signaling required for endothelial cell proliferation, migration, and survival. The primary result is the inhibition of angiogenesis in both physiological and pathological contexts.

In addition to VEGFR2 inhibition, SU5416 functions as an agonist of the aryl hydrocarbon receptor (AHR). Activation of AHR by SU5416 leads to the upregulation of indoleamine 2,3-dioxygenase (IDO), an enzyme that promotes the differentiation of regulatory T cells and modulates immune responses. This dual mechanism underpins the utility of SU5416 in both cancer and immunology research [see mechanistic insights]. This article extends previous coverage by providing updated quantitative benchmarks and clarifying AHR-mediated immune effects.

Evidence & Benchmarks

• SU5416 (Semaxanib) inhibits VEGF-induced mitogenesis in HUVECs with an IC₅₀ of 0.04±0.02 μM in serum-free conditions (https://www.apexbt.com/su5416.html).
• In vivo, daily intraperitoneal administration of SU5416 at 1–25 mg/kg significantly inhibits tumor growth in murine xenograft models, with no observed mortality at high doses (https://doi.org/10.1186/s12931-024-03036-1).
• SU5416 is insoluble in water and ethanol, but soluble at ≥11.9 mg/mL in DMSO; stock solutions remain stable at -20°C for several months (https://www.apexbt.com/su5416.html).
• SU5416 acts as an agonist of the aryl hydrocarbon receptor (AHR), leading to IDO induction and enhanced regulatory T cell differentiation under defined in vitro conditions (https://ruxolitinib-phosphate.com/index.php?g=Wap&m=Article&a=detail&id=49).
• Combined administration of Sugen5416 and hypoxia is used to induce pulmonary arterial hypertension (PAH) in animal models, enabling study of angiogenic and immune mechanisms in disease (https://doi.org/10.1186/s12931-024-03036-1).

Applications, Limits & Misconceptions

Applications:

• Cancer research—SU5416 is widely used to study tumor angiogenesis, tumor vascularization suppression, and anti-angiogenic therapeutic strategies.
• Immunology—The compound’s ability to modulate AHR and IDO pathways positions it for studies on immune tolerance, regulatory T cell biology, and autoimmune disease models.
• Pulmonary arterial hypertension—Combined with hypoxia, SU5416 enables the creation of reproducible PAH models for biomarker discovery and pathophysiology studies (Zhang et al., 2024).

This article clarifies and extends the practical workflow coverage from 'Applied Workflows & Advanced Applications', by providing updated in vivo dosing parameters and new insights on immune modulation.

Common Pitfalls or Misconceptions

• SU5416 is not soluble in water or ethanol; improper solvent selection reduces bioavailability.
• It does not broadly inhibit all VEGF receptors; specificity is highest for VEGFR2 (Flk-1/KDR), with limited off-target activity.
• SU5416 does not induce angiogenesis; it inhibits VEGF-mediated pathways and should not be used where vascular promotion is required.
• The compound is not approved for clinical human use; it is strictly for research applications.
• Prolonged exposure or high concentrations in vitro may cause non-specific cytotoxicity; titrate carefully.

Workflow Integration & Parameters

SU5416 (Semaxanib) is delivered by APExBIO as a powder suitable for reconstitution in DMSO at ≥11.9 mg/mL. For in vitro experiments, effective concentrations range from 0.01–100 μM, with most angiogenesis assays optimized at 0.1–10 μM. Warming to 37°C or sonication enhances dissolution. Stock solutions are stable for several months at -20°C. In vivo, daily intraperitoneal dosing at 1–25 mg/kg is validated for tumor xenograft studies, with no reported mortality at the upper range [SU5416 product page]. For detailed protocol optimization and troubleshooting, see 'Practical Strategies with SU5416', which this article updates with new tolerability and dosing benchmarks.

Workflow integration is facilitated by SU5416's compatibility with standard angiogenesis, tumor growth, and immune modulation assays. Product SKU A3847 is referenced in multiple peer-reviewed studies and internal guides for reproducibility and data comparability.

Conclusion & Outlook

SU5416 (Semaxanib) is a validated, potent, and selective VEGFR2 tyrosine kinase inhibitor, widely used for dissecting angiogenic mechanisms and tumor biology. Its dual activity as an AHR agonist broadens its scope to immune modulation and autoimmune disease models. As shown by recent proteomic studies and validated animal models, SU5416 remains an essential tool in translational vascular and cancer research (Zhang et al., 2024). Researchers should consult the APExBIO SU5416 (Semaxanib) VEGFR2 inhibitor product page for further specifications and up-to-date usage recommendations. For a deeper strategic perspective, see 'Harnessing SU5416 (Semaxanib): Mechanistic and Strategic Advances'; this article provides more granular technical and workflow detail, especially for immune modulation research.